医药生物/医疗服务 凯莱英（002821.SZ） 2026 年 01 月 28 日 投资评级：买入（首次） | 日期 | 2026/1/27 | | --- | --- | | 当前股价(元) | 99.98 | | 一年最高最低(元) | 125.50/59.90 | | 总市值(亿元) | 360.80 | | 流通市值(亿元) | 316.94 | | 总股本(亿股) | 3.61 | | 流通股本(亿股) | 3.17 | | 近 3 个月换手率(%) | 87.67 | 股价走势图 -30% 0% 30% 60% 90% 2025-02 2025-06 2025-10 凯莱英 沪深300 数据来源：聚源 小分子 CDMO 龙头，多肽与小核酸共筑新增长极 ——公司首次覆盖报告 余汝意（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 小分子基石稳固，常规业务韧性凸显，签单企稳回升 凯莱英是全球领先的小分子 CDMO 企业，深耕行业二十五年，正处于从单一小 分子业务向"小分子+新兴业务"双轮驱动转型的关键期。随着公司新兴业务快速 放量，业绩韧性凸显。短期看，大订单高基数影 ...

Summary of Sichuan Shuangma Conference Call Company Overview - Sichuan Shuangma has transformed from a single cement enterprise to a dual-main business company focusing on equity investment and biomedicine, continuously divesting cement assets and actively entering the biomedicine sector through acquisitions like Shenzhen Jianyuan and participation in the acquisition of Wuxi Shengji [2][5]. Core Business Structure - The company's main business structure is divided into three parts: private equity investment (approximately 30% of revenue), biomedicine (approximately 28%), and cement/building materials (approximately 42%) by 2025. The profit contribution from private equity investment is expected to reach around 90%, while the remaining profit will mainly come from biomedicine, with the cement business being flat or slightly loss-making [3]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are expected to be CNY 1.455 billion, CNY 1.802 billion, and CNY 2.587 billion, representing year-on-year growth of 35.37%, 23.85%, and 43.58% respectively. Net profit attributable to the parent company is projected to be CNY 491 million, CNY 1.132 billion, and CNY 1.475 billion, with growth rates of 58.32%, 131.03%, and 30.32% respectively [2][9]. Investment and Growth Strategy - The company has a strong focus on biomedicine as its second main business, with significant acquisitions aimed at accelerating its presence in the sector. The acquisition of Shenzhen Jianyuan for CNY 1.6 billion and participation in the acquisition of Wuxi Shengji are key steps in this strategy [5][8]. Market Perception and Valuation - The market perceives uncertainty regarding the company's equity investment business, particularly due to the low current contribution of the biomedicine sector to overall revenue and profit. Concerns include potential declines in management fee income as the first batch of funds enters the exit phase and the uncertain scale and timing of excess return realizations [2][6]. Value Reassessment Opportunities - There is a belief that Sichuan Shuangma has opportunities for value reassessment due to the high certainty of cash returns from its equity investment business. IDG Capital's strong investment management capabilities and the successful IPOs of several hard-tech projects are expected to provide substantial cash returns, estimated at CNY 10.4 billion from two managed funds [7][9]. Historical Context and Strategic Shift - The entry of IDG in 2016 marked a significant shift for Sichuan Shuangma, transitioning from a cement-focused company to one that also manages equity funds. The company has been divesting outdated cement assets since 2017, with only one cement plant remaining as of 2024 [4]. Conclusion - Sichuan Shuangma's strategic focus on biomedicine and equity investment, combined with strong projected financial growth and potential for value reassessment, positions the company favorably for future performance despite current market uncertainties [2][7].